CI
NBIX icon

Cavalier Investments’s Neurocrine Biosciences NBIX Stock Holding History

Cavalier Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,700
Closed -$578K – 179
2018
Q3 		$578K Buy
+4,700
New +$533K 0.17% 107

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Cavalier Investments's NBIX Position: Q4 2018 in Review

Cavalier Investments sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 4,700 shares — an estimated $578K sold.

Cavalier Investments first reported a position in NBIX in Q3 2018 and held it in 1 quarter. The position peaked at $578K in Q3 2018. 330 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

  • Cavalier Investments reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
  • Cavalier Investments sold 4,700 Neurocrine Biosciences shares in Q4 2018, an estimated $578K.
  • Cavalier Investments first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 1 quarter.
  • Cavalier Investments's Neurocrine Biosciences position peaked at $578K in Q3 2018.
  • 330 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on Cavalier Investments's 13F filing for Q4 2018, filed 1 Feb 2019.